
Indinavir; Crixivan®

In-vitro Data
| Cell |
Strain |
EC50 |
IC50 |
Units |
TI |
Reference |
| MT-4 |
HIV-1(IIIB) |
EC95=0.1* |
>400 |
µM |
- |
1 |
| PBMC |
HIV-1(112 PRIM ISOL) |
EC95=0.1* |
- |
µM |
- |
1 |
*EC95 is the concentration of drug that inhibits p24 production in infected cells
by 95%.
| Data in NIAID Chemical Database |
 |
| Clinical Information Link |
 |
Links to Drug Resistance Databases
References
- VACCA, J.P.; DORSEY, B.D.; SCHLEIF, W.A.; LEVIN, R.B.; MCDANIEL, S.L.; DARKE,
P.L.; ZUGAY, J.; QUINTERO, J.C.; BLAHY, O.M.; ROTH, E.; SARDANA V.V.; SCHLABACH
A.J.; GRAHAM P.I.; CONDRA J.H.; GOTLIB L.; ANDERSON, P.S.; EMINI, E.A.; HUFF,
J.R.; ET.AL., L-735,524: AN ORALLY BIOAVAILABLE HIV-1 PROTEASE INHIBITOR.
PROC NATL ACAD SCI 91(9):4096-4100 (1994).
